AR036304A1 - Sistema nuevo de liberacion de droga autoemulsionable - Google Patents

Sistema nuevo de liberacion de droga autoemulsionable

Info

Publication number
AR036304A1
AR036304A1 ARP020103215A ARP020103215A AR036304A1 AR 036304 A1 AR036304 A1 AR 036304A1 AR P020103215 A ARP020103215 A AR P020103215A AR P020103215 A ARP020103215 A AR P020103215A AR 036304 A1 AR036304 A1 AR 036304A1
Authority
AR
Argentina
Prior art keywords
proton pump
pump inhibitor
pharmaceutical composition
composition
drug release
Prior art date
Application number
ARP020103215A
Other languages
English (en)
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Publication of AR036304A1 publication Critical patent/AR036304A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/407—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
    • A61K31/381—Heterocyclic compounds having sulfur as a ring hetero atom having five-membered rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/4035—Isoindoles, e.g. phthalimide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/405—Indole-alkanecarboxylic acids; Derivatives thereof, e.g. tryptophan, indomethacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/683—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols
    • A61K31/685—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols one of the hydroxy compounds having nitrogen atoms, e.g. phosphatidylserine, lecithin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
    • A61K9/1075—Microemulsions or submicron emulsions; Preconcentrates or solids thereof; Micelles, e.g. made of phospholipids or block copolymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4858—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A61P29/02—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] without antiinflammatory effect

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Rheumatology (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Dispersion Chemistry (AREA)
  • Pain & Pain Management (AREA)
  • Emergency Medicine (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Composición farmacéutica adecuada para la administración oral, en la forma de un pre-concentrado de emulsión, que comprende: (i) uno o más NSAID(s) que liberan NO; ii) uno o más surfactantes de los cuales, al menos uno es un fosfolípido; dicha composición forma una emulsión aceite en agua in situ luego del contacto con los fluidos gastrointestinales. Opcionalmente, la composición puede también comprender un aceite adicional o grasa semi-sólida. Se pueden incluir uno o más alcoholes de cadena corta en la composición. Una combinación con un inhibidor de la bomba de protones. La composición farmacéutica es útil para el tratamiento del dolor y la inflamación. Un kit que comprende una composición farmacéutica de acuerdo con la presente en una forma de dosis unitaria, combinada con un inhibidor de la bomba de protones, dicho inhibidor de la bomba de protones tiene un revestimiento entérico.
ARP020103215A 2001-09-07 2002-08-27 Sistema nuevo de liberacion de droga autoemulsionable AR036304A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
SE0102993A SE0102993D0 (sv) 2001-09-07 2001-09-07 New self emulsifying drug delivery system

Publications (1)

Publication Number Publication Date
AR036304A1 true AR036304A1 (es) 2004-08-25

Family

ID=20285273

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP020103215A AR036304A1 (es) 2001-09-07 2002-08-27 Sistema nuevo de liberacion de droga autoemulsionable

Country Status (9)

Country Link
US (1) US7815933B2 (es)
EP (1) EP1427392B1 (es)
JP (1) JP4656483B2 (es)
AR (1) AR036304A1 (es)
AT (1) ATE386503T1 (es)
DE (1) DE60225154T2 (es)
ES (1) ES2300471T3 (es)
SE (1) SE0102993D0 (es)
WO (1) WO2003022249A1 (es)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6852739B1 (en) 1999-02-26 2005-02-08 Nitromed Inc. Methods using proton pump inhibitors and nitric oxide donors
IT1319202B1 (it) 2000-10-12 2003-09-26 Nicox Sa Farmaci per le malattie a base infiammatoria.
CA2491127A1 (en) 2002-07-03 2004-01-15 Nitromed, Inc. Nitrosated nonsteroidal antiinflammatory compounds, compositions and methods of use
CA2493156A1 (en) 2002-07-29 2004-02-05 Nitromed, Inc. Cyclooxygenase-2 selective inhibitors, compositions and methods of use
JP4634144B2 (ja) 2002-08-01 2011-02-16 ニコックス エスエー ニトロソ化プロトンポンプ阻害剤、組成物および使用方法
SE0301880D0 (sv) * 2003-06-25 2003-06-25 Astrazeneca Uk Ltd New drug delivery composition
GB0818473D0 (en) * 2008-10-08 2008-11-12 Probio Nutraceuticals As Composition
US9968557B1 (en) 2011-02-09 2018-05-15 Florida A&M University Method of preparing modified multilayered microstructures with enhanced oral bioavailability
US20120213855A1 (en) * 2011-02-17 2012-08-23 Cima Labs Inc. Dosage forms for weakly ionizable compounds
WO2013142482A1 (en) 2012-03-20 2013-09-26 Particle Dynamics International, Llc Gelling agent-based dosage form
EP2833976A1 (en) * 2012-04-03 2015-02-11 Unilever N.V. A personal care composition
WO2017218894A1 (en) 2016-06-16 2017-12-21 Cutispharma, Inc. Composition and method for proton pump inhibitor suspension
CN110179750A (zh) * 2019-06-17 2019-08-30 四川九章生物科技有限公司 一种绿原酸自乳化组合物及其用途
US10751333B1 (en) 2019-07-16 2020-08-25 Cutispharma, Inc. Compositions and kits for omeprazole suspension
US11633478B2 (en) 2019-07-16 2023-04-25 Azurity Pharmaceuticals, Inc. Compositions and kits for Omeprazole suspension

Family Cites Families (84)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE7804231L (sv) 1978-04-14 1979-10-15 Haessle Ab Magsyrasekretionsmedel
US4369182A (en) * 1978-09-27 1983-01-18 A. Nattermann & Cie Gmbh Inflammation-preventing pharmaceutical composition of oral administration
CY1398A (en) 1981-09-04 1987-12-18 Glaxo Group Ltd Pharmaceutical compositions containing non-steroidal anti-inflammatory agents
US4546273A (en) 1983-01-11 1985-10-08 Burroughs Corporation Dynamic re-programmable PLA
JPS59227870A (ja) 1983-06-07 1984-12-21 Yamanouchi Pharmaceut Co Ltd 新規２−グアニジノチアゾリン誘導体ならびにその製造法
US4554276A (en) 1983-10-03 1985-11-19 Pfizer Inc. 2-Amino-5-hydroxy-4-methylpyrimidine derivatives
US4522826A (en) 1984-02-08 1985-06-11 Richardson-Vicks Inc. Analgesic and anti-inflammatory compositions comprising diphenhydramine and methods of using same
US4552899A (en) 1984-04-09 1985-11-12 Analgesic Associates Cough/cold mixtures comprising non-steroidal anti-inflammatory drugs
IL75400A (en) 1984-06-16 1988-10-31 Byk Gulden Lomberg Chem Fab Dialkoxypyridine methyl(sulfinyl or sulfonyl)benzimidazoles,processes for the preparation thereof and pharmaceutical compositions containing the same
JPS6150978A (ja) 1984-08-16 1986-03-13 Takeda Chem Ind Ltd ピリジン誘導体およびその製造法
AU4640985A (en) 1984-08-31 1986-03-06 Nippon Chemiphar Co. Ltd. Benzimidazole derivatives
US4766117A (en) 1984-10-11 1988-08-23 Pfizer Inc. Antiinflammatory compositions and methods
US4704278A (en) 1984-10-17 1987-11-03 American Home Products Corp (Del) Fluidized magaldrate suspension
US4676984A (en) 1985-08-14 1987-06-30 American Home Products Corp. Rehydratable antacid composition
US5043358A (en) 1986-03-04 1991-08-27 Bristol-Myers Squibb Company Gastroprotective process
US5037815A (en) 1986-03-04 1991-08-06 Bristol-Myers Squibb Co. Non-steroidal anti-inflammatory compositions protected against gastrointestinal injury with a combination of certain H1 - and H2 -receptor blockers
US4965065A (en) 1986-04-29 1990-10-23 Bristol-Myers Squibb Company Gastroprotective process and compositions
US4757060A (en) 1986-03-04 1988-07-12 Bristol-Myers Company Non-steroidal anti-inflammatory compositions protected against gastrointestinal injury with a combination of certain H1 and H2, receptor blockers
GB2189698A (en) 1986-04-30 1987-11-04 Haessle Ab Coated omeprazole tablets
US5260333A (en) 1986-08-08 1993-11-09 Bristol Myers Squibb Company Effect of a combination of a terbutaline, diphenhydramine and ranitidine composition on gastrointestinal injury produced by nonsteroidal anti-inflammatory compositions
GB8630273D0 (en) 1986-12-18 1987-01-28 Til Medical Ltd Pharmaceutical delivery systems
EP0320550A1 (en) 1987-12-18 1989-06-21 Bristol-Myers Company Non steroidal anti-inflammatory drug composition containing H1 blockers, H2 blockers, beta adrenergic agonists or combinations thereof and an alkalizing agent
SE8804629D0 (sv) 1988-12-22 1988-12-22 Ab Haessle New therapeutically active compounds
NZ235877A (en) 1989-11-02 1992-09-25 Mcneil Ppc Inc Composition comprising acetaminophen or nsaid and an h 1 or h 2 receptor blocker and/or proton pump inhibitor for treating overindulgence
US5204118A (en) 1989-11-02 1993-04-20 Mcneil-Ppc, Inc. Pharmaceutical compositions and methods for treating the symptoms of overindulgence
CA2104684A1 (en) 1991-03-04 1992-09-05 Mahdi B. Fawzi Salts/ion pairs of non-steroidal anti-inflammatory drugs in various dosage forms
DE4131678A1 (de) 1991-04-13 1992-10-15 Beiersdorf Ag Stabile multiple emulsionen
ES2130152T3 (es) 1991-12-06 1999-07-01 Glaxo Group Ltd Medicamentos para tratar dolencias inflamatorias o para analgesia que contienen un nsaid y ranitidina/citrato de bismuto.
AU3247593A (en) 1991-12-20 1993-07-28 Warner-Lambert Company Therapeutic combinations useful in the treatment of gastroesophageal reflux disease
US5294433A (en) 1992-04-15 1994-03-15 The Procter & Gamble Company Use of H-2 antagonists for treatment of gingivitis
IT1256345B (it) 1992-08-20 1995-12-01 Esteri nitrici di derivati dell'acido 2-(2,6-di-alo-fenilammino) fenilacetico e procedimento per la loro preparazione
JPH08502254A (ja) 1992-09-29 1996-03-12 メルク エンド カンパニー インコーポレーテッド イブプロフェン−ｈ▲下２▼拮抗薬配合物
IT1256450B (it) * 1992-11-26 1995-12-05 Soldato Piero Del Esteri nitrici con attivita' farmacologica e procedimento per la loro preparazione
US5686105A (en) 1993-10-19 1997-11-11 The Procter & Gamble Company Pharmaceutical dosage form with multiple enteric polymer coatings for colonic delivery
CH686761A5 (de) * 1993-05-27 1996-06-28 Sandoz Ag Galenische Formulierungen.
SE9301830D0 (sv) 1993-05-28 1993-05-28 Ab Astra New compounds
DK66493D0 (da) 1993-06-08 1993-06-08 Ferring A S Praeparater, isaer til brug ved behandling af inflammatoriske tarmsygdomme eller til at opnaa forbedret saarheling
SE9302396D0 (sv) 1993-07-09 1993-07-09 Ab Astra A novel compound form
WO1995006925A1 (fr) 1993-09-01 1995-03-09 A3P S.A.R.L. Dispositif de detection d'intrusion dans un batiment ou un vehicule par detection d'infrasons et/ou d'ondes de pression et procede de detection d'intrusion
US6054136A (en) 1993-09-30 2000-04-25 Gattefosse S.A. Orally administrable composition capable of providing enhanced bioavailability when ingested
US6312704B1 (en) 1993-09-30 2001-11-06 Gattefosse, S.A. Orally administrable composition capable of providing enhanced bioavailability when ingested
FR2710535B1 (fr) 1993-09-30 1995-11-24 Gattefosse Ets Sa Composition à usage pharmaceutique ou cosmétique apte à former une microémulsion.
DE69412109T2 (de) 1993-10-06 1999-01-21 Nicox Sa Salzetersaüreester mit entzündungshemmender und/oder schmerzlindernder wirkung und verfahren zu deren herstellung
US5514663A (en) 1993-10-19 1996-05-07 The Procter & Gamble Company Senna dosage form
EP0724441A1 (en) 1993-10-19 1996-08-07 The Procter & Gamble Company Picosulphate dosage form
US6025395A (en) 1994-04-15 2000-02-15 Duke University Method of preventing or delaying the onset and progression of Alzheimer's disease and related disorders
US5643960A (en) 1994-04-15 1997-07-01 Duke University Method of delaying onset of alzheimer's disease symptoms
JP4043046B2 (ja) * 1994-05-10 2008-02-06 ニコックス エス エイ 消炎、鎮痛および抗血栓活性を有するニトロ化合物およびそれらの組成物
UA41946C2 (uk) 1994-07-08 2001-10-15 Астра Актієболаг Оральна фармацевтична складова одинична дозована форма у вигляді таблетки, спосіб її одержання, упаковка у вигляді блістера та спосіб інгібування секреції шлункової кислоти і/або лікування шлунково-кишкових запальних захворювань
SE9500478D0 (sv) 1995-02-09 1995-02-09 Astra Ab New pharmaceutical formulation and process
AU692255B2 (en) * 1995-04-24 1998-06-04 Yissum Research Development Company Of The Hebrew University Of Jerusalem Self-emulsifiable formulation producing an oil-in-water emulsion
US5955451A (en) * 1995-05-12 1999-09-21 The University Of Texas System Board Of Regents Methods of enhancing the therapeutic activity of NSAIDS and compositions of zwitterionic phospholipids useful therein
EP0760237A1 (en) * 1995-08-30 1997-03-05 Cipla Limited Oil-in-water microemulsions
SE9600070D0 (sv) * 1996-01-08 1996-01-08 Astra Ab New oral pharmaceutical dosage forms
US6231888B1 (en) 1996-01-18 2001-05-15 Perio Products Ltd. Local delivery of non steroidal anti inflammatory drugs (NSAIDS) to the colon as a treatment for colonic polyps
WO1998022117A1 (en) 1996-11-22 1998-05-28 The Procter & Gamble Company Compositions for the treatment of gastrointestinal disorders containing bismuth, and nsaid and one or more antimicrobials
SE510666C2 (sv) 1996-12-20 1999-06-14 Astra Ab Nya Kristallmodifikationer
US6160020A (en) 1996-12-20 2000-12-12 Mcneill-Ppc, Inc. Alkali metal and alkaline-earth metal salts of acetaminophen
SE510643C2 (sv) 1997-06-27 1999-06-14 Astra Ab Termodynamiskt stabil omeprazol natrium form B
RU2202346C2 (ru) * 1997-07-29 2003-04-20 Фармация Энд Апджон Компани Фармацевтическая композиция для кислотных липофильных соединений в форме самоэмульгирующейся композиции
JP2001515854A (ja) 1997-09-11 2001-09-25 ニュコメデ ダンマルク アクティーゼルスカブ 非ステロイド性抗炎症薬物質（ＮＳＡＩＤｓ）の改良された開放性多重−単位組成物
EP1032425A1 (en) 1997-10-31 2000-09-06 Monsanto Company Gellan gum tablet coating
DE19801811B4 (de) 1998-01-19 2004-12-23 Stada Arzneimittel Ag Pharmazeutische Zubereitung zur oralen Verabreichung
EP1056457A4 (en) 1998-01-30 2006-10-25 Sepracor Inc S-LANSOPRAZOLE COMPOSITIONS AND METHODS OF USE
WO1999038513A1 (en) 1998-01-30 1999-08-05 Sepracor Inc. R-lansoprazole compositions and methods
AU3843999A (en) 1998-05-07 1999-11-23 Elan Corporation, Plc Solvent/cosolvent free microemulsion and emulsion preconcentrate drug delivery systems
EP0984012A3 (en) * 1998-08-31 2001-01-10 Pfizer Products Inc. Nitric oxide releasing oxindole prodrugs with analgesic and anti-inflammatory properties
KR100695562B1 (ko) 1998-09-28 2007-03-15 워너-램버트 캄파니 엘엘씨 Ｈｐｍｃ 캡슐을 이용한 장 및 결장에의 전달방법
US6485747B1 (en) 1998-10-30 2002-11-26 Monsanto Company Coated active tablet(s)
CN1236813C (zh) 1998-12-11 2006-01-18 药品处理公司 水难溶性药物的自乳化组合物
US6635281B2 (en) 1998-12-23 2003-10-21 Alza Corporation Gastric retaining oral liquid dosage form
US6267985B1 (en) 1999-06-30 2001-07-31 Lipocine Inc. Clear oil-containing pharmaceutical compositions
EP1165091B1 (en) * 1999-03-31 2005-01-26 PHARMACIA & UPJOHN COMPANY Pharmaceutical emulsions for retroviral protease inhibitors
IL145220A0 (en) 1999-05-20 2002-06-30 Par Pharmaceutical Inc Stabilized composition based on pyridinyl-sulfinyl-benzimidazoles and process
TWI243672B (en) * 1999-06-01 2005-11-21 Astrazeneca Ab New use of compounds as antibacterial agents
US6787164B2 (en) 2000-02-23 2004-09-07 Bioselect Innovations, Inc. Composition and method for treating the effects of diseases and maladies
SE0000773D0 (sv) 2000-03-08 2000-03-08 Astrazeneca Ab New formulation
SE0000774D0 (sv) * 2000-03-08 2000-03-08 Astrazeneca Ab New formulation
US20020044962A1 (en) 2000-06-06 2002-04-18 Cherukuri S. Rao Encapsulation products for controlled or extended release
SE0002476D0 (sv) 2000-06-30 2000-06-30 Astrazeneca Ab New compounds
US6544556B1 (en) 2000-09-11 2003-04-08 Andrx Corporation Pharmaceutical formulations containing a non-steroidal antiinflammatory drug and a proton pump inhibitor
US20020045184A1 (en) 2000-10-02 2002-04-18 Chih-Ming Chen Packaging system
FR2818905A1 (fr) 2000-12-28 2002-07-05 Cll Pharma Compositions pharmaceutiques colloidales micellaires renfermant un principe actif lipophile
AR036354A1 (es) 2001-08-31 2004-09-01 Takeda Chemical Industries Ltd Preparacion solida

Also Published As

Publication number Publication date
ES2300471T3 (es) 2008-06-16
DE60225154D1 (de) 2008-04-03
EP1427392B1 (en) 2008-02-20
US7815933B2 (en) 2010-10-19
US20040248974A1 (en) 2004-12-09
JP2005504788A (ja) 2005-02-17
DE60225154T2 (de) 2009-02-26
SE0102993D0 (sv) 2001-09-07
ATE386503T1 (de) 2008-03-15
EP1427392A1 (en) 2004-06-16
WO2003022249A1 (en) 2003-03-20
JP4656483B2 (ja) 2011-03-23

Similar Documents

Publication Publication Date Title
AR036304A1 (es) Sistema nuevo de liberacion de droga autoemulsionable
DE60103627D1 (de) SELBSTEMULGIERENDES ARZNEISTOFFVERABREICHUNGSSYSTEM, wobei das Fettmittel optional ist
AR035642A1 (es) Uso de una composicion de celecoxib para el alivio rapido del dolor
ES2167061T3 (es) Formas de dosificacion para mejorar la disfuncion erectil en pacientes de sexo masculino.
CL2004000931A1 (es) Pelicula consumible adaptada para adherirse y disolverse en la cavidad bucal que comprende un almidon modificado y un agente farmaceuticamente activo.
AR043258A1 (es) Formulacion, complejo antiacido omeprazol - liberacion inmediata, para supresion rapida y sostenida de la acidez gastrica
UY27533A1 (es) Composiciones farmacéuticas que contienen oxibutinina
AR047841A1 (es) Metodos y composiciones para el tratamiento de transtornos inmunoinflamatorios
AR005281A1 (es) Composicion farceutica oral , procedimientos para su manufactura y uso de esa composicion farmaceutica para la preparacion de medicamentos. .
CO5650245A2 (es) Formulaciones dispersable de un agente anti-inflamatorio
AR057378A1 (es) Formulaciones de diclofenac y metodos para usarlas
ECSP088165A (es) Formulaciones liquidas
ES2624577T3 (es) Formulación líquida que comprende un agonista de los receptores alfa-2 (por ejemplo, clonidina) y oxibutinina (agente antimuscarínico) para el tratamiento de sialorrea
AR027554A1 (es) Nuevo sistema de adminstracion de farmacos autoemulsionante
UY27296A1 (es) Composición farmacéutica que contiene mosaprida y pancreatina
PE20030830A1 (es) Ambroxol para el tratamiento de estados dolorosos en la cavidad bucal y faringea
ES2526359T3 (es) Formulación galénica oral que comprende ketorolaco y vitaminas del complejo B, en la que la vitamina B6 se encuentra en una capa externa separada del resto de principios activos
CL2004000767A1 (es) Unidad de dosificacion oral que comprende un agente antagonista de bombas de protones y excipientes de caracter basico; procedimiento para su preparacion, utiles para tratar enfermedades causadas por una secrecion aumentada de acidos gastricos.
AR027555A1 (es) Nuevo sistema de administracion de farmacos emulsionante
AR030964A1 (es) Una formulacion farmaceutica con una matriz que forma un gel hidrofilico, formulacion que comprende una o mas sustancias activas, y metodo para preparar tal formulacion que tiene una liberacion prolongada sustancialmente independiente de la fuerza ionica
ECSP982720A (es) Formulacion que contiene un opioide en combinacion con un agonista adrenergico y su utilizacion como analgesico
TH100976B (th) ระบบนำส่งยาแบบอีมัลชิฟายตัวเองชนิดใหม่
AR047791A1 (es) Formulacion adyuvante conteniendo una emulsion oleosa con aceite de jojoba
PE20010174Z (es) Sistema de administracion de vitaminas, minerales y/o plantas medicinales para seres humanos via oral mediante un dispositivo de bombeo en spray
AR044928A1 (es) Metodo para inducir la ovulacion usando un modulador no polipeptidico de nivel de camp

Legal Events

Date Code Title Description
FA Abandonment or withdrawal